## Supplemental Figures

## Fusing Dual-Event Datasets for Mycobacterium Tuberculosis Machine Learning Models and their Evaluation

Sean Ekins<sup>†,‡\*</sup>, Joel S. Freundlich<sup>§, $\parallel$ </sup> and Robert C. Reynolds<sup>⊥</sup>

<sup>+</sup> Collaborative Drug Discovery, 1633 Bayshore Highway, Suite 342, Burlingame, CA 94010, USA.

<sup>‡</sup> Collaborations in Chemistry, 5616 Hilltop Needmore Road, Fuquay-Varina, NC 27526, USA.

<sup>§</sup> Department of Medicine, Center for Emerging and Reemerging Pathogens, Rutgers University – New Jersey Medical School, 185 South Orange Avenue, Newark, NJ 07103, USA.

<sup>II</sup> Department of Pharmacology & Physiology, Rutgers University – New Jersey Medical School, 185 South Orange Avenue, Newark, NJ 07103, USA.

<sup>⊥</sup> University of Alabama at Birmingham, College of Arts and Sciences, Department of Chemistry, 1530 3<sup>rd</sup> Avenue South, Birmingham, AL 35294-1240, USA.

\*To whom correspondence should be addressed. E-mail: <u>ekinssean@yahoo.com</u>

Running title: Fusing datasets for Mtb



Supplemental Figure 1. ARRA dose response and cytotoxicity Bayesian model: good features from FCFP\_6.



Supplemental Figure 2. ARRA dose response and cytotoxicity Bayesian model: bad features from FCFP\_6.

Supplemental Figure 3. Combined dose response and cytotoxicity Bayesian model: good features from FCFP\_6.





Supplemental Figure 4. Combined dose response and cytotoxicity Bayesian model: bad features from FCFP\_6.

Supplemental Figure 5. Examples of GSK compounds (see Molecule Name) clustering with TB Mobile compounds known to target specific *Mtb* targets (see Target Gene 1).

А



В





D

|                  |            | 39 | mmpL3 (Rv0206c) 1 |
|------------------|------------|----|-------------------|
| ays as           | GSK937733A | 39 |                   |
| C and the second | GSK798463A | 39 | 1                 |

С



## F



Е